Recent Publications by Biologix Corporation: |  |
A pan-HER approach for cancer therapy: background, current status and future development.
BACKGROUND: The human EGF receptor (EGFR or HER) family and its cognate... | 10th December, 2008
| Receptor BioLogix, Inc., Palo Alto, CA 94303, USA.
| Expert Opin Biol Ther. 2009 Jan;9(1):97-110.
DOI Direct Link |
Rational Optimization of a Bispecific Ligand Trap Targeting EGF Receptor Family Ligands.
The human EGF receptor (HER) family members cooperate in malignancy. Of... | 3rd December, 2008
| Receptor BioLogix, Inc., Palo Alto, California, USA.
| Mol Med. 2008 Nov 23.
DOI Direct Link |
Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.
All four members of the human epidermal growth factor (EGF) receptor (HER)... | 13th November, 2008
| Receptor BioLogix, Inc., 3350 West Bayshore Road, Suite 150, Palo Alto, CA
| Mol Cancer Ther. 2008 Oct;7(10):3223-36.
DOI Direct Link |
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.
The human EGFR (HER) family is essential for communication between many... | 5th November, 2008
| Receptor BioLogix, Inc.,
| J Clin Invest. 2008 Nov;118(11):3574-81.
DOI Direct Link |
Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.
INTRODUCTION: Despite the advent of biological therapies for the treatment... | 3rd July, 2008
| Receptor BioLogix,
| Arthritis Res Ther. 2008;10(4):R73. Epub 2008 Jul 1.
DOI Direct Link |
→View more Biologix Corporation research publications. |
This page has been viewed 190 times since April 2007, the link to the organisation's website has been followed 0 times